Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30 results about "Nkg2d receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The NKG2D receptor: sensing stressed cells. The activating killer cell lectin-like receptor NKG2D plays a key role in the natural killer (NK) cell-mediated lysis of tumours and infected cells.
Method for differentiating human induced pluripotent stem cells into natural killer cells
PendingCN113801846AStrong ability to secrete cytokinesStrong cell killing abilityBlood/immune system cellsCell culture active agentsNatural Killer Cell Inhibitory ReceptorsNkg2d receptor
The invention belongs to the technical field of biology, and relates to a method for differentiating human induced pluripotent stem cells into natural killer cells. The method comprises the following steps of 1, differentiating the human induced pluripotent stem cells to form endothelial progenitor cells with expression of KDR+CD73+; 2, performing endothelial-blood conversion on the endothelial progenitor cells with the expression of KDR+CD73+ to form NK progenitor cells with the expression of CD34-CD45+; and 3, further differentiating the NK progenitor cells into NK cells with expression of CD56+CD3-. The NK cells produced by the scheme provided by the invention highly express NKG2D receptors, and have stronger cytokine secretion ability and tumor killing ability.
Owner:HELP STEM CELL INNOVATIONS CO LTD
Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
PendingCN112040971AGood effectLow efficacyPolypeptide with localisation/targeting motifOrganic active ingredientsAnticarcinogenActivated Natural Killer Cell
A combination therapy of a cancer with a multi-specific binding protein that bind a tumor associated antigen, the NKG2D receptor, and CD16, in combination with a second anti-cancer agent are described. Also described are pharmaceutical compositions of the multi-specific binding protein, and therapeutic methods useful for the treatment of cancer in combination with a second anti-cancer agent.
Owner:DRAGONFLY THERAPEUTICS INC
Proteins binding psma, nkg2d and cd16
PendingCN110913902AImmunoglobulin superfamilyImmunoglobulins against cell receptors/antigens/surface-determinantsCD16Nkg2d receptor
Owner:DRAGONFLY THERAPEUTICS INC
Proteins binding NKG2D, CD16, and EGFR, CCR4, or PD-L1
PendingCN113004391APolypeptide with localisation/targeting motifLectin superfamilyCD16Nkg2d receptor
Owner:DRAGONFLY THERAPEUTICS INC
Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1)
PendingCN111432832AHybrid immunoglobulinsImmunoglobulins against cell receptors/antigens/surface-determinantsCD16Binding site
The invention provides multi-specific binding proteins that bind to a tumor-associated antigen CLEC12A and to the NKG2D receptor and CD16 receptor on natural killer cells. One aspect of the inventionprovides a protein that incorporates a first antigen-binding site that binds NKG2D; a second antigen-binding site that binds CLEC12A; and an antibody Fc domain, a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16. The antigen-binding sites may each incorporate an antibody heavy chain variable domain and an antibody light chain variable domain, or one or moreof the antigen-binding sites may be a single domain antibody, such as a VHH antibody or a VNAR antibody. Another aspect of the invention provides a method of treating cancer in a patient. The method comprises administering to a patient in need thereof a therapeutically effective amount of the multi-specific binding protein.
Owner:DRAGONFLY THERAPEUTICS INC
Proteins binding nkg2d, cd16 and a tumor-associated antigen
PendingCN111315782AImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsNkg2d receptorCD16
Owner:DRAGONFLY THERAPEUTICS INC
Tumor therapy
Neoplasia is treated by administering to a mammalian host a composition comprising ligands for the NKG2D receptor. In addition, other NKG2D ligands, proteins specific for the neoplastic cells and cytokines may be included to enhance the immune response. The composition may be cells comprising expression constructs for the ligands, liposomes or combinations of protein molecules.
Owner:RAULET DAVID H +1
Proteins binding nkg2d, cd16 and a tumor-associated antigen
Multi-specific binding proteins that bind NKG2D receptor, CD 16, and a tumor- associated antigen (e.g, B7-H3, L1CAM, FLT1, KDR, TNC, TNN, CSPG4, BST1, SELF, CD200, INSR (HHF5), ITGA6, MELTF, PECAM1, or SLC1A5) are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
Owner:DRAGONFLY THERAPEUTICS INC
Multispecific binding proteins targeting CAIX, ANO1, mesothelin,TROP2, or claudin-18.2
PendingCN112661853AHybrid immunoglobulinsImmunoglobulins against cell receptors/antigens/surface-determinantsCD16Nkg2d receptor
The present invention relates to multispecific binding proteins targeting CAIX, ANO1, mesothelin, TROP2, or a claudin-18.2. In particular. Specifically, the present invention describes multispecific binding proteins that bind to the NKG2D receptor, CD16 and a tumor-associated antigen selected from the group consisting of carbonic anhydrase 9 (CAIX), calcitonin 1 (ANO1), mesothelin, TROP2, CEA and claudin-18.2, as well as pharmaceutical compositions and methods of treatment useful in the treatment of cancer.
Owner:DRAGONFLY THERAPEUTICS INC
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
PendingCN110944651ALow efficacyImprove securityNervous disorderPeptide/protein ingredientsNkg2d receptorAntigen receptors
Multi-specific binding proteins that bind a tumor associated antigen, the NKG2D receptor, and CD 16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
Owner:DRAGONFLY THERAPEUTICS INC
Proteins binding nkg2d, cd16 and a tumor-associated antigen
PendingCN113164570AImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsCD16Nkg2d receptor
Multi-specific binding proteins that bind NKG2D receptor, CD 16, and a tumor- associated antigen selected from c-MET, KIT, F3, IGF1R, Lewis Y, MUC13, MUC4, MCAM, LRRC32, sialyl-Tn, gpA33, GD3, GM2, EPHA3, TNFRSF10A, TNFSF11, CD74, and PMEL are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
Owner:DRAGONFLY THERAPEUTICS INC
Antibody variable domains targeting the nkg2d receptor
Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described.Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.
Owner:DRAGONFLY THERAPEUTICS INC
Reducing fratricide of immune cells expressing nkg2d-based receptors
PendingCN112218943AImmunoglobulin superfamilyPeptide/protein ingredientsAdoptive cellular therapyReceptor
The present application relates to the field of immunotherapy, more particularly to the manufacture of cells for adoptive cell therapy. Provided herein are methods to prevent and / or reduce fratricideduring manufacturing of such cells, particularly of cells expressing a chimeric NKG2D receptor. Also provided are cells and compositions comprising cells in which fratricide is prevented and / or reduced.
Owner:CELYAD SA
Proteins binding NKG2D, CD16 and a tumor-associated antigen
PendingCN113004417AHybrid immunoglobulinsImmunoglobulins against cell receptors/antigens/surface-determinantsCD16Nkg2d receptor
Owner:DRAGONFLY THERAPEUTICS INC
Proteins binding gd2, nkg2d and cd16
PendingCN110891976AImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsCD16Nkg2d receptor
Owner:DRAGONFLY THERAPEUTICS INC
T cells modified with synthetic receptors containing single ITAM signaling motif
PendingCN114729319APolypeptide with localisation/targeting motifAntibody mimetics/scaffoldsIntracellular signallingNkg2d receptor
The present invention relates to [alpha] [beta] T cells genetically modified to express a recombinant chimeric antigen receptor (CAR) wherein the recombinant CAR comprises (a) an extracellular domain comprising an antigen binding region, (b) a transmembrane domain, (c) a co-stimulatory signaling domain, and (d) an intracellular signaling domain wherein the extracellular domain comprises an extracellular domain of the NKG2D receptor, and wherein the intracellular signaling domain comprises an immune receptor tyrosine-based activation motif (ITAM); a recombinant CAR for modifying an alpha beta T cell; a pharmaceutical composition comprising genetically modified [alpha] [beta] T cells; methods of treating cancer or tumors using the genetically modified [alpha] [beta] T cells; and methods of making genetically modified alpha beta T cells. In one embodiment, a genetically modified [alpha] [beta] T cell comprises a CAR comprising an extracellular domain of the NKG2D receptor, an IgG4 hinge region, a CD28 transmembrane domain, a 4-1BB co-stimulatory signaling domain, and a DAP 12 domain comprising a single ITAM.
Owner:NAT UNIV OF SINGAPORE
Fusion protein for natural killer cell specific crispr/cas system and use thereof
PendingUS20220243186A1Good effectPolypeptide with localisation/targeting motifSpecial deliveryNkg2d receptorCell membrane
Provided are a fusion protein used in a CRISPR / Cas system, and a complex including the same and use thereof. Since the gene editing complex including the fusion protein of the present disclosure includes an NKG2D ligand capable of binding to NKG2D expressed on the membrane of natural killer cells, it may be specifically delivered to NKG2D receptor-expressing cells or natural killer cells. Since it may be effectively delivered into the cells through endocytosis of NKG2D without a carrier, a target gene or a target DNA of NKG2D receptor-expressing cells or natural killer cells may be manipulated using the complex.
Owner:KOREA INST OF SCI & TECH
A protein binding nkg2d, cd16 and a tumor-associated antigen
PendingCN112437672AConvenient treatmentLibrary screeningImmunoglobulins against cell receptors/antigens/surface-determinantsCD16Nkg2d receptor
Owner:DRAGONFLY THERAPEUTICS INC
EpCAM-CD16-NKG2D trispecific antibody and application thereof
The invention relates to an EpCAM-CD16-NKG2D trispecific antibody and an application thereof. The EpCAM-CD16-NKG2D trispecific antibody comprises an EpCAM binding domain, a CD16 binding domain and an NKG2D ligand binding domain. According to the EpCAM-CD16-NKG2D trispecific antibody constructed by the invention, an NKG2D receptor is added on the basis of an EpCAM * CD16 bispecific antibody, and the EpCAM-CD16-NKG2D trispecific antibody can be used for immune cells not only to target tumor cells expressing EpCAM in an epithelial state, but also to target tumor cells expressing NKG2D ligands in a mesenchymal state, or target tumor cells expressing both the EpCAM and the NKG2D ligands in a mixed state, so that stronger ability of immune cells to resist migration tumors can be mediated.
Owner:THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY
Bivalent antibody directed against NKG2D and tumor associated antigens
A polypeptide is disclosed that binds tumor-associated antigens (TAA) on the surface of cancer cells and a NKG2D receptor. The NKG2D receptor is expressed on the surfaces of killer cells such as natural killer cells, T cells, natural killer T cells, and gamma delta T cells. In some cases, the TAA is CS-1 or EGFRvIII. Also disclosed are polynucleotides encoding the disclosed polypeptides, vectors comprising the disclosed polynucleotides, and host cells comprising the disclosed vectors. Also disclosed are bivalent antibodies comprising the disclosed polypeptides. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies. Also disclosed are methods of treating cancer in a subject using the disclosed bi-specific antibodies.
Owner:OHIO STATE INNOVATION FOUND
Proteins binding nkg2d, cd16 and flt3
PendingCN111132698AHybrid immunoglobulinsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenCD16
Owner:DRAGONFLY THERAPEUTICS INC
Soluble NK-CAR fusion protein as well as preparation method and application of soluble NK-CAR fusion protein in drug for mediating immune cells to kill tumor cells
ActiveCN114292337AEasy to purifyShorten production timePeptide/protein ingredientsAntibody ingredientsAntigenDimer
The invention discloses a soluble NK-CAR fusion protein, a preparation method and an application of the soluble NK-CAR fusion protein in a drug for mediating immune cells to target tumor cells. The fusion protein is composed of an MICA extracellular region, a single-chain antibody and a human IgG Fc terminal from an amino terminal to a carboxyl terminal. A nucleotide sequence for coding the protein is inserted into an eukaryotic expression vector and transfected to an HEK293 suspension cell for protein expression, then purification is carried out through an SPA column, the protein is in a dimer state in an aqueous solution, a CD20 single-chain antibody of the protein can be combined with a CD20 antigen on a target cell, an MICA terminal is combined with an NKG2D receptor on an NK cell to activate the NK cell to play a role in specifically killing the target cell, and the target cell is killed. The invention lays a foundation for development and application of biological medicines for specifically killing tumor target cells by mediating NK cells and CD8 + T cells.
Owner:CENT SOUTH UNIV
Protein binding nkg2d, cd16 and a fibroblast activation protein
PendingCN112423788AConvenient treatmentHybrid immunoglobulinsAntibody mimetics/scaffoldsAutoimmune conditionCD16
Multi-specific binding proteins that bind NKG2D receptor, CD16, and fibroblast activation protein (FAP) are described, as well as pharmaceutical compositions and therapeutic methods of the multi- specific binding proteins useful for the treatment of cancer, autoimmune disease, or fibrosis.
Owner:DRAGONFLY THERAPEUTICS INC
Proteins binding cd123, nkg2d and cd16
PendingCN110914305AAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsCD16Nkg2d receptor
Owner:DRAGONFLY THERAPEUTICS INC
A chimeric antigen receptor targeting HER2 and co-expressing PD1-mica fusion protein, its expression vector and application
ActiveCN110684121BEfficient killingPolypeptide with localisation/targeting motifImmunoglobulin superfamilySingle-Chain AntibodiesNatural Killer Cell Inhibitory Receptors
The invention discloses a chimeric antigen receptor targeting HER2 and co-expressing PD1-MICA fusion protein as well as its expression vector and application, which belong to the field of tumor immunity drugs. The chimeric antigen receptor includes: sequentially linked signal peptide, single-chain antibody targeting HER2, CD8α hinge region and transmembrane region, co-stimulatory factor, intracellular signal peptide, P2A linking peptide, IL2 signal peptide, PD1 cell Extracellular domain and MICA extracellular domain. The chimeric antigen receptor secretes PD1-MICA fusion protein while specifically targeting HER2-positive tumor cells, targets PD-L1 / PD-L2 positive tumor cells, and blocks PD1 and PD-L1 / PD-L1 of T cells L2 inhibits the signal, and at the same time, the extracellular region of MICA can bind to the NKG2D receptor to activate NK cells, so as to realize the purpose of CAR-T cells to effectively kill HER2-positive tumor cells in vivo.
Owner:华夏源细胞工程集团股份有限公司
A protein binding nkg2d, cd16 and ror1 or ror2
PendingCN111263643APeptide/protein ingredientsImmunoglobulins against cytokines/lymphokines/interferonsProtein proteinNkg2d receptor
Owner:DRAGONFLY THERAPEUTICS INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com